The buyout gives Promethera control of a TNF receptor 1 inhibitor it hopes will amplify the effects of cell therapy HepaStem.

Constellation raised $100 million that will bankroll a cancer epigenetics asset through the clinic.

Hitting the IPO target would bring the preclinical anti-aging startup’s fundraising haul up toward $300 million.

The drug impressed in a small trial, raising hopes that ITBMed can snag a limited, near-term approval while running a pivotal study to expand its use. 

The Terns deal is a poster child of "Lilly China Innovation and Partnerships," a new model in place of Lilly's Shanghai R&D center shuttered…

Former Fierce 15 winner Arvinas has got off a strong $55 million series C as it looks to bring its cancer candidates into the clinic.

The vehicle sets Sofinnova up to invest in 15 late-stage private and public drug and medical device companies.

The total falls short of the amount Unum set out to raise but leaves it with enough cash to advance two cell therapies in four clinical trials.

Tempest Therapeutics is chasing Incyte and Bristol-Myers with what it thinks is a best-in-class IDO inhibitor.